PMID- 19894090
OWN - NLM
STAT- MEDLINE
DCOM- 20100125
LR  - 20211020
IS  - 1619-0904 (Electronic)
IS  - 1434-7229 (Linking)
VI  - 12
IP  - 3
DP  - 2009
TI  - Neurohumoral response and clinical effectiveness of continuous aortic flow 
      augmentation in patients with decompensated heart failure.
PG  - 166-71
LID - 10.1007/s10047-009-0466-3 [doi]
AB  - The increasing number of patients with progressive or exacerbated heart failure 
      that is refractory to medical treatment necessitates the development of 
      innovative cardiac assist devices. The aim of this study was to investigate 
      whether a new percutaneously inserted system, which allows continuous aortic flow 
      augmentation (CAFA), could be shown to be clinically effective with neurohormonal 
      benefit in patients admitted with decompensated heart failure. Patients with 
      exacerbations of chronic heart failure were recruited for the study. A 
      percutaneous circulation assist device (Cancion system) promoting CAFA was 
      implanted for up to 4 days in each patient. Clinical improvement was evaluated by 
      measuring the clinical status according to the New York Heart Association (NYHA) 
      classification and biochemical parameters including troponin and B-type 
      natriuretic peptide (BNP) as markers of cardiac necrosis and cardiac overload; 
      these parameters were measured before, during, and after CAFA treatment. The 
      decrease in BNP was determined after implantation, reaching, on average, a 
      maximum decrease of 57% at 72 h (P = 0.04). The neurohumoral response remained 
      significant (P < 0.05) up to 120 h after implantation, with a decrease in BNP 
      levels of 37%, on average, compared to baseline values. Troponin I did not show 
      any significant change during mechanical assistance (P > 0.2). All patients had 
      improved clinical status according to the NYHA classification, and the 
      improvement lasted for more than 1 week. Percutaneous heart-assist devices 
      promoting CAFA offer clinical improvement and a neurohumoral response, with a 
      significant BNP reduction in severe exacerbation of chronic heart failure that is 
      refractory to medical treatment.
FAU - Neumann, Till
AU  - Neumann T
AD  - Clinic of Cardiology, Department of Internal Medicine, University of Essen, 
      Essen, Germany. till.neumann@uk-essen.de
FAU - Aidonides, Georg
AU  - Aidonides G
FAU - Konorza, Thomas
AU  - Konorza T
FAU - Krings, Peter
AU  - Krings P
FAU - Erbel, Raimund
AU  - Erbel R
LA  - eng
PT  - Journal Article
DEP - 20090919
PL  - Japan
TA  - J Artif Organs
JT  - Journal of artificial organs : the official journal of the Japanese Society for 
      Artificial Organs
JID - 9815648
RN  - 0 (Biomarkers)
RN  - 0 (Troponin I)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aorta
MH  - Biomarkers/blood
MH  - Blood Flow Velocity
MH  - Chronic Disease
MH  - Heart Failure/*blood/*therapy
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Troponin I/*blood
EDAT- 2009/11/07 06:00
MHDA- 2010/01/26 06:00
CRDT- 2009/11/07 06:00
PHST- 2008/11/25 00:00 [received]
PHST- 2009/05/13 00:00 [accepted]
PHST- 2009/11/07 06:00 [entrez]
PHST- 2009/11/07 06:00 [pubmed]
PHST- 2010/01/26 06:00 [medline]
AID - 10.1007/s10047-009-0466-3 [doi]
PST - ppublish
SO  - J Artif Organs. 2009;12(3):166-71. doi: 10.1007/s10047-009-0466-3. Epub 2009 Sep 
      19.